The Enhanced Group, the telehealth company behind May's controversial "steroid Olympics" in Las Vegas, reported a net loss of nearly $62 million in its second-quarter earnings, released this week. The bulk of that financial hit came from hosting the Enhanced Games, a one-of-a-kind athletic competition that allowed participants to use performance-enhancing drugs typically forbidden in professional sports. The event, which critics labeled the "steroid Olympics," failed to deliver both competitive excitement and commercial success — only one world record was broken, in a sport where records fall frequently.
Enhanced Group brought in $17.7 million during the second quarter, but most of that revenue came from sponsorships connected to the games rather than from the digital telehealth platform that forms the company's foundation. The telehealth business sells FDA-approved treatments including peptides, testosterone injections, and GLP-1s for weight loss, but little detail is available about how that core operation is performing. The company, which was founded in 2023 and went public earlier this year at a $1.2 billion valuation, is backed by investors including Peter Thiel and staffed by veterans from the crypto, AI, and biotech sectors.
The earnings report casts doubt on earlier claims by Enhanced executives that the games would become an annual tradition, according to the report. The company would need to generate significantly more revenue or accept losing tens of millions of dollars each year to sustain such an event. Enhanced may already be shifting strategy — the report highlights the recent debut of Enhanced Breakers, an online series that "operates at a fraction of the cost of a full Games event" while keeping athletes competing and sponsors engaged year-round.
Despite Enhanced Group's struggles, the broader peptide industry is expanding rapidly. A recent decision by the Trump administration's Food and Drug Administration to reclassify numerous substances that have occupied a legal gray area has boosted the sector, though an additional review process is still required before those substances can be sold freely. The FDA's parent agency, the U.S. Department of Health and Human Services, is overseen by Robert F. Kennedy Jr., whose unconventional health views have drawn criticism from medical professionals who characterize his thinking as dangerous. Silicon Valley has emerged as a hub for peptide startups like Superpower and Noho Labs, which are capitalizing on the tech industry's enthusiasm for biohacking and trendy health supplements. The sector's expansion is outpacing regulatory oversight, with state governments struggling to establish governing frameworks. Enhanced Group's pivot to lower-cost content formats suggests the company recognizes that spectacle alone won't sustain a business model built on performance medicine, and that profitability may require retreating from grand ambitions to more modest, repeatable programming. The broader regulatory tailwinds favoring peptides could offer Enhanced a lifeline, but only if the company can demonstrate its telehealth platform has genuine traction beyond the hype surrounding a single controversial event.